[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617707":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":27,"locations":27,"responsibleParty":39,"collaborators":27,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":27,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":27,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":68,"whyStopped":27,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":27},{"fullName":5,"class":6},"Science & Research Islamic Azad University Branch Khozestan","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Light fasting and Magnesium Supplementation","EXPERIMENTAL","Participants follow a Light Fasting diet during the first month, designed with gradual caloric restriction and intermittent fasting days, followed by a maintenance diet tailored to individual needs during the second month. They receive magnesium supplementation (500 mg\u002Fday in two doses of 250 mg), for the full 2-month intervention.",[13,14],"Behavioral: Light fasting","Dietary Supplement: Magnesium supplementation",{"label":16,"type":17,"description":18,"interventionNames":19},"Light fasting and Placebo","PLACEBO_COMPARATOR","Participants follow the same Light Fasting and maintenance diet schedule as the intervention group and receive a placebo supplement identical in appearance to the magnesium tablets, taken twice daily, for the full 2-month intervention.",[13,20],"Dietary Supplement: Placebo",[22,28,33,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"BEHAVIORAL","Light fasting","Participants follow a Light Fasting diet during the first month, designed with gradual caloric restriction and intermittent fasting days, followed by a maintenance diet tailored to individual needs during the second month.",[9],null,{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":27},"DIETARY_SUPPLEMENT","Magnesium supplementation","Participants receive magnesium supplementation (500 mg\u002Fday in two doses of 250 mg), for the full 2-month intervention.",[9],{"type":23,"name":24,"description":25,"armGroupLabels":34,"otherNames":27},[16],{"type":29,"name":36,"description":37,"armGroupLabels":38,"otherNames":27},"Placebo","Participants receive a placebo supplement identical in appearance to the magnesium tablets, taken twice daily, for the full 2-month intervention.",[16],{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Behnood Abbasi","Faculty member","100617707","light-fasting-diet-and-magnesium-in-polycystic-ovary-syndrome-pcos-100617707",false,"NCT07322120","Light Fasting Diet and Magnesium in Polycystic Ovary Syndrome (PCOS)","Investigation of the Effect of Light Fasting Diet Combined With Magnesium Supplementation on Lipid Profile, Lipid Peroxidation, and C-Reactive Protein (CRP) Levels in Women With Polycystic Ovary Syndrome (PCOS).","Inclusion Criteria:\n\n1. People between the ages of 19 and 65\n2. People with a body mass index (BMI) ≤ 25\n3. Diagnosis of polycystic ovary syndrome by a specialist based on the Rotterdam criteria\n\nExclusion Criteria:\n\n1. Failure of the participant to cooperate during the study\n2. Use of drug therapy that affects carbohydrate or fat metabolism (including oral contraceptives, insulin sensitizers, antiepileptic drugs, antipsychotics, statins, and fish oil) within the past 6 months.\n3. Planning for pregnancy, pregnant, or breastfeeding\n4. In the perimenopausal stage\n5. Low blood pressure\n6. Presence of other diseases (such as congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, hyperprolactinemia, diabetes, thyroid disease, severe cardiovascular, gastrointestinal, renal, and hepatic diseases)\n7. Performing high-intensity exercise","FEMALE","19 Years","65 Years",{"count":54,"type":55},46,"ESTIMATED","INTERVENTIONAL",[58],"NA","Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, which is associated with hormonal imbalances, dyslipidemia, chronic inflammation, and increased oxidative stress, and can increase the risk of cardiovascular and metabolic diseases. Evidence suggests that nutritional interventions play an important role in improving metabolic outcomes in these patients.\n\nThis study is a randomized, triple-blind, controlled clinical trial designed to investigate the effect of a light fasting diet combined with magnesium supplementation on lipid profile, lipid peroxidation (malondialdehyde), and C-reactive protein (CRP) levels in women with PCOS. In this study, 46 eligible women were randomly divided into two groups receiving a light fasting diet with magnesium supplementation or placebo, and changes in biochemical and anthropometric indices were evaluated before and after 8 weeks of intervention.",[61],"Polycystic Ovary Syndrome",[61,63,64,65,66,67],"Light Fasting","Magnesium","Lipid Profile","Lipid Peroxidation","C-Reactive Protein","NOT_YET_RECRUITING","2025-12-22",{"date":71,"type":72},"2026-01-07","ACTUAL",{"date":74,"type":55},"2026-02-20",{"date":76,"type":55},"2026-06-22",{"name":41,"class":6}]